Dukagjin Blakaj | Radiation Oncology | Best Researcher Award

Published on by Cell Biologist

Prof. Dukagjin Blakaj | Radiation Oncology | Best Researcher Award

Prof. Dukagjin Blakaj, The Ohio State University, United States

Dr. Dukagjin M. Blakaj, MD, PhD, is a distinguished physician-scientist and academic leader in radiation oncology, specializing in proton therapy. Currently serving as the Vice Chair of Clinical Operations and holding the prestigious Drs. Malati and Ganesh Potdar Endowed Professorship at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, he brings visionary leadership in patient-centered oncology care. With dual degrees in medicine and biochemistry, Dr. Blakaj integrates clinical expertise with advanced translational research. He is renowned for developing innovative radiotherapy protocols, advancing artificial intelligence applications in oncology, and mentoring future clinician-scientists. His work significantly influences treatment outcomes for head and neck cancers, including HPV-related oropharyngeal cancer, and is published in top-tier journals. A respected thought leader and collaborative partner, Dr. Blakaj embodies excellence in academic medicine, multidisciplinary team leadership, and compassionate patient care.

Publication Profile: 

Google Scholar

Scopus

Orcid

Education:

Dr. Blakaj’s educational path is both extensive and interdisciplinary. He earned his MD, PhD, and MS in Biochemistry from the Albert Einstein College of Medicine in New York, where he focused on molecular interactions in biological systems. Before that, he completed both a BA in Chemistry and Molecular Biology & Biophysics and an MA in Chemistry from Wesleyan University in Middletown, CT. His doctoral work explored protein-RNA interactions, laying the groundwork for his scientific rigor and precision. This strong biochemical foundation supports his innovative clinical research in radiation oncology and immunotherapy. His education highlights a consistent pattern of academic excellence and intellectual curiosity, equipping him with a rare blend of clinical insight and research acumen that continues to impact cancer treatment paradigms worldwide.

Professional Experience:

Dr. Dukagjin Blakaj is the Vice Chair of Clinical Operations in Radiation Oncology and Drs. Malati and Ganesh Potdar Endowed Professor in Proton Therapy at OSUCCC – James Cancer Hospital. As a senior faculty member, he has led transformative improvements in clinical care, quality assurance, and translational oncology research. His multidisciplinary collaboration extends across surgery, radiology, oncology, and data science, driving innovations such as AI-guided treatment protocols and digital health integration. Dr. Blakaj has also played a critical role in operationalizing proton therapy and implementing personalized cancer therapies. His background spans high-impact clinical trials, program development, and mentorship. The combination of clinical leadership and academic scholarship positions him as a strategic thinker with practical, evidence-driven execution. His commitment to precision medicine and patient-centered care distinguishes him among modern radiation oncologists.

Awards and Honors:

Dr. Blakaj has received numerous accolades that reflect his clinical excellence, research innovation, and service to the academic community. Notably, he was awarded the Drs. Malati and Ganesh Potdar Endowed Professorship in Radiation Oncology – Proton Therapy (effective June 2025), the highest honor granted by Ohio State University. His ABR Volunteer Service Award (July 2025) highlights his contributions to professional standards and education. He was selected for the James Outstanding Physician Peer Award for exemplary leadership, professionalism, and collaboration (August 2024). Additionally, his abstract ranked in the Top 7 of 146 presentations at ACRO, underscoring his research’s national impact. Dr. Blakaj’s consistent recognition across service, research, and teaching is a testament to his dedication, integrity, and influence in the field of oncology.

Research Focus:

Dr. Blakaj’s research is centered on optimizing cancer treatment outcomes through precision radiation therapy, immunotherapy integration, and the application of artificial intelligence in oncology. He focuses primarily on head and neck cancers, with additional emphasis on HPV-associated oropharyngeal carcinoma, FLASH radiotherapy, and treatment response prediction using circulating tumor DNA and inflammatory indices. He co-leads interdisciplinary studies leveraging machine learning, big data, and digital health tools to personalize care and reduce treatment toxicity. His research is both translational and clinically grounded, often influencing national clinical practice guidelines and multi-center trials. As a key contributor to high-impact publications, Dr. Blakaj has established himself as a thought leader in adaptive radiotherapy and survivorship outcomes. His pioneering work in proton therapy protocols and patient-reported outcomes continues to bridge the gap between innovative science and practical oncology care.

Publications Top Notes: 

  1. An integrated ML-based prognostic model in head and neck cancer using inflammatory markers and financial toxicity

  2. Vertebral endplate disruption and compression fracture risk: Expanded radiotherapy analysis

  3. Nasopharyngeal carcinoma in nonendemic regions: Characteristics and treatment outcomes

  4. Emerging paradigms in radiation oncology: Evolution and patient-centric care

  5. FLASH radiotherapy: From in vivo data to clinical translation

  6. Digital health tools in radiation oncology: Development and implementation review

  7. ctDNA as a response marker in HPV-associated oropharyngeal carcinoma: A pilot study

  8. AI, machine learning, and big data in radiation oncology

  9. Predicting cisplatin tolerability in elderly head and neck cancer patients

  10.  Tobacco, marijuana, and alcohol use impact on survival in metastatic head and neck cancer

Conclusion:

Dr. Dukagjin M. Blakaj is a highly qualified, forward-thinking researcher whose body of work exemplifies excellence in translational oncology. He brings together advanced clinical practice, cutting-edge research, and visionary leadership to improve cancer care outcomes and drive future innovations in radiation therapy.

Given his sustained productivity, multidisciplinary leadership, and contributions to patient-centered care models, Dr. Blakaj is a deserving and outstanding nominee for the Best Researcher Award.

Amr Hanbali | Therapeutic use of Cellular therapy in cancer treatment | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Amr Hanbali | Therapeutic use of Cellular therapy in cancer treatment | Best Researcher Award

Assoc. Prof. Dr. Amr Hanbali | King Faisal Specialist Hospital & Research Center | Saudi Arabia

Dr. Amr AlHanbali is a dual-certified Hematology and Oncology consultant with over 18 years of experience in malignant and benign hematological conditions. Based at King Faisal Specialist Hospital & Research Center in Riyadh, Saudi Arabia, he specializes in hematologic malignancies and stem cell transplantation. Dr. AlHanbali previously served as a senior staff physician and Associate Fellowship Program Director at Henry Ford Health System in Detroit, Michigan. Recognized for his academic involvement, he holds teaching appointments at Wayne State University and Alfaisal University. Known for his dedication to clinical mentorship, he has trained numerous medical students, residents, and fellows. He is actively involved in research and is a member of several prestigious medical organizations including the American Society of Hematology and American Society of Clinical Oncology. With expertise ranging from bone marrow procedures to managing complex hematologic disorders, Dr. AlHanbali is a respected leader in the field of hematology and stem cell transplantation.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contribution

    • Over 17 peer-reviewed publications, including impactful case reports, national guidelines, and original research in hematology, oncology, and stem cell transplantation.

    • Active contributor to national guidelines on multiple myeloma, reflecting leadership in shaping national healthcare standards in KSA.

  2. Dual Academic and Clinical Roles

    • Combines academic excellence (as faculty at Wayne State University and Alfaisal University) with hands-on clinical expertise at a premier institution (King Faisal Specialist Hospital & Research Center).

  3. Innovative Focus in Hematology and Transplantation

    • Research into underexplored areas such as hepatitis B reactivation post-rituximab, genetic donor match outcomes, and therapies for AL amyloidosis.

  4. International Exposure and Leadership

    • Experience across the U.S. and Saudi Arabia, influencing programs in both systems.

    • Played a key role in training and selecting future hematology-oncology fellows in the U.S.

  5. Mentorship and Capacity Building

    • Mentored numerous trainees, enhancing research culture among younger clinicians.

Areas for Improvement:

  1. Higher Impact Publications Needed

    • While the volume and variety of research are commendable, more publications in top-tier journals (NEJM, Lancet, Blood, JCO) could boost citation impact and visibility.

  2. Research Grants and Collaborative Trials

    • Pursuing multicenter studies, international collaborations, or industry-sponsored clinical trials would further elevate his profile and expand research funding sources.

  3. Technological Innovation/Patents

    • Exploring biotech innovation, AI in diagnostics, or cellular therapy patents could position him among the top medical innovators.

Education:

Dr. Amr AlHanbali completed his Bachelor of Medicine and Surgery from the University of Jordan in 1999. He pursued medical training in the United States, starting with an internal medicine residency (2001–2004) at Henry Ford Health System, Detroit. He continued his specialization with a fellowship in Hematology and Oncology (2004–2007) at the same institution. During his training, he also undertook elective rotations in Pediatric Cardiology and Gastroenterology at the University of Texas Medical Branch, Galveston, further enriching his academic exposure. He is certified by the American Board of Internal Medicine in Internal Medicine (2004), Hematology (2007), and Oncology (2007). Dr. AlHanbali holds academic titles as a Clinical Assistant Professor at Wayne State University, Detroit, and Adjunct Associate Professor at Alfaisal University, Riyadh. His educational background reflects a strong foundation in internal medicine, with a deep focus on hematology and oncology, further supported by teaching and research excellence.

Experience:

Dr. AlHanbali’s clinical career spans over 18 years, currently serving as Hematology and Stem Cell Transplant Consultant at King Faisal Specialist Hospital & Research Center in Riyadh since 2013. Prior to this, he held multiple leadership roles at Henry Ford Health System, Detroit, including Senior Staff Physician and Associate Fellowship Program Director (2007–2013). His medical expertise covers the diagnosis and treatment of a wide range of hematologic malignancies such as leukemia, lymphoma, multiple myeloma, and myeloproliferative disorders. Dr. AlHanbali also has extensive experience in stem cell transplantation, intrathecal chemotherapy, and bone marrow biopsy. He has been instrumental in resident selection and curriculum development for fellowship programs in hematology and oncology. His work bridges clinical excellence with academic mentorship, guiding numerous trainees and junior physicians. In addition to patient care, he is involved in clinical guideline development and research, particularly in the field of multiple myeloma and transplant outcomes.

Research Focus:

Dr. Amr AlHanbali’s research is centered on hematologic malignancies, particularly multiple myeloma, lymphoma, leukemia, and stem cell transplantation. His work explores novel therapeutic approaches, transplant outcomes, disease progression, and treatment-related complications. He has contributed significantly to research on hepatitis B reactivation, chemotherapy-induced toxicities, and the protective role of comorbidities like diabetes in cancer metastasis. As an active member of the Saudi Myeloma Working Group, he has co-authored national guidelines for both newly diagnosed and relapsed/refractory multiple myeloma. His studies also examine health disparities in cancer care, including outcomes among African American populations and the impact of familial genetics in donor matches. With over a dozen peer-reviewed publications and case reports in high-impact journals, Dr. AlHanbali continues to push forward understanding in clinical hematology and oncology. He combines bedside insights with academic rigor to shape evidence-based practice and improve treatment outcomes in cancer and transplant medicine.

Publications Top Notes:

  1.  Mediastinal Hematoma With SVC Syndrome From A Central Venous Catheter Insertion – CHEST, 2003

  2.  Diabetes Has Protective Effect Against Metastasis in Non-Small Cell Lung Cancer – Arch Intern Med, 2007

  3.  Delayed Hepatitis B Viral Replication Post-Rituximab & Fludarabine in Waldenstrom Macroglobulinemia – Am J Hematol, 2007

  4.  Acute Pancreatitis Induced by Adult Precursor B-cell ALL – South Med J, 2007

  5.  Hypersensitivity Reaction of Mylotarg with Platelet Transfusion – Am J Health Syst Pharm, 2007

  6.  Incidence of Hepatitis B Reactivation after Rituximab Therapy – Am J Hematol, 2009

  7. Outcomes After Auto-SCT in African Americans with Multiple Myeloma – Bone Marrow Transplant, 2009

  8.  HER-2 Status May Change in Recurrent Breast Cancer – Cancer Research, 2009

  9.  Compartment Syndrome as Presentation of Chronic Myelogenous Leukemia – J Gen Intern Med, 2010

  10.  Use of Insulin and its Effect on Survival in NSCLC – J Clin Oncol, 2009

Conclusion:

Dr. Amr AlHanbali demonstrates a stellar blend of clinical expertise, research productivity, academic mentorship, and leadership in hematology and oncology. His research contributions have practical implications in areas such as multiple myeloma, leukemia, transplant immunology, and chemotherapy safety.

He is highly deserving of recognition and stands out as a top contender for a Best Researcher Award, particularly in the categories of clinical research excellence, translational hematology, and medical education integration with research.

Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Dr. Yanlan Wang, Stanford, United States

Dr. Yanlan Wang is a distinguished postdoctoral research fellow at Stanford University’s Department of Pathology. She works in the esteemed Dr. Gerald Crabtree’s lab, where her research revolves around leveraging molecular glues to reprogram cancer drivers and trigger apoptosis. With a strong background in immuno-oncology, antibody engineering, and small molecule therapeutics, Dr. Wang has made significant contributions to targeted cancer therapies. Her interdisciplinary collaborations, notably with Dr. Nathanael Gray’s group, have explored the role of transcription factor complex-inducing compounds (TCIPs) in MLL-rearranged leukemia. Dr. Wang brings a rich international research experience from China and the U.S., with a career spanning translational medicine, biotechnology innovation, and academic excellence. She is known for her rigorous approach to scientific inquiry, collaborative spirit, and prolific publication record. Her passion for understanding and overcoming the mechanisms of cancer resistance positions her as a future leader in oncology drug development and precision medicine.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Outstanding Research Focus
    Dr. Wang’s work on molecular glues and transcription factor modulators represents cutting-edge approaches in cancer therapy, especially in targeting previously undruggable pathways.

  2. High Impact Publications
    With multiple first-author and co-corresponding author papers (e.g., J Immunol Methods 2025, Leukemia & Lymphoma 2020, Clin Pharmacol Ther 2021), Dr. Wang has demonstrated a strong track record in both fundamental and translational cancer research.

  3. Innovation & Translational Impact
    Her efforts in bispecific antibody engineering, IL-15 therapeutics, and AKR1C3-targeted prodrugs show clear applications in oncology drug development, bridging the lab and clinic.

  4. Prestigious Collaborations
    Collaborating with renowned researchers such as Dr. Gerald Crabtree and Dr. Nathanael Gray at Stanford indicates high confidence and integration in world-class research circles.

  5. Recognition & Awards
    She has received the Coxe Fellowship at Stanford and multiple merit-based scholarships, highlighting academic excellence and innovation.

  6. Leadership and Multidisciplinary Skills
    Dr. Wang has led several projects, authored high-level papers, and mentored junior researchers, showcasing both technical and leadership capability.

🔄 Areas for Improvement:

  1. Greater International Presentation Exposure
    Although she has strong publication credentials, more visibility through international oral presentations, keynote addresses, or panel roles would amplify her leadership profile.

  2. Independent Grant Record
    While she is currently in a postdoctoral role, seeking independent funding (e.g., K99/R00, early-career PI grants) would position her more competitively for independent investigator status.

  3. Patent or Commercial Translation
    Given the translational nature of her work, pursuit of intellectual property filings or biotech partnerships would further highlight impact.

🎓 Education:

Dr. Yanlan Wang began her academic journey at Xiangya School of Medicine, Central South University, where she earned her MBBS (M.D. equivalent) in June 2012. She continued at The Second Xiangya Hospital for her clinical residency, completing her M.S. in June 2015. Her pursuit of scientific excellence led her to earn a doctorate (M.D. equivalent to PhD) from Sun Yat-sen University in June 2018, with a research focus on microbial immunology and tumor biology. This diverse educational background gave her a solid foundation in both clinical medicine and biomedical research, allowing her to bridge translational gaps in cancer research. Her early training emphasized immunotherapy, molecular biology, and oncology, all of which paved the way for her postdoctoral work in cutting-edge labs. Her education reflects a consistent upward trajectory, marked by prestigious institutions, interdisciplinary training, and a seamless integration of clinical and scientific disciplines.

🔬 Experience:

Dr. Yanlan Wang is currently a postdoctoral research fellow in Dr. Gerald Crabtree’s lab at Stanford University, where she focuses on manipulating cancer cell pathways using molecular glues. Her prior research in China included pivotal roles in biotechnology innovation, including bispecific antibody engineering, prodrug design, and immune-oncology drug development. She has also collaborated extensively with Dr. Nathanael Gray’s lab at Stanford, exploring the therapeutic potential of TCIPs in leukemia. Dr. Wang’s hands-on experience includes multiplex screening platforms, flow cytometry, in vivo tumor models, and translational immunotherapy development. Over the years, she has taken leadership roles in preclinical projects, manuscript authorship, and international scientific presentations. Her diverse roles—from clinical residency to laboratory innovation—reflect her capability to translate complex scientific findings into therapeutic strategies. Dr. Wang has also mentored junior researchers and worked across multiple disciplines, underscoring her adaptability, leadership potential, and deep commitment to cancer research.

🏅 Awards and Honors:

Dr. Yanlan Wang’s excellence has been recognized through several prestigious awards. At Stanford, she received the Coxe Fellowship in 2021, honoring outstanding postdoctoral researchers. During her doctoral training, she earned the Special Award of Merit for the BJ-001 Project at BJ Bioscience Inc. in 2019 for her impactful translational research. Her academic merit was consistently acknowledged through the Bidi Scholarship (2016–2017) and Daxiang Scholarship (2015–2016) at Sun Yat-sen University. These honors underscore her commitment to scientific excellence, innovation, and translational impact in oncology and immunotherapy. Her ability to receive awards across both academic and industrial settings highlights her versatility and the real-world relevance of her work. These distinctions serve as a testament to her leadership in cancer drug development, collaborative effectiveness, and contribution to next-generation therapeutic discoveries.

🔍 Research Focus:

Dr. Yanlan Wang’s research lies at the intersection of cancer biology, molecular pharmacology, and immunotherapy. At Stanford, she investigates how molecular glues can be used to hijack cancer drivers and activate apoptosis, offering a novel route for targeted cancer therapies. Her work involves multiplex molecular glue screening, understanding protein degradation pathways, and designing synthetic lethality strategies. In collaboration with Dr. Nathanael Gray, she is also studying Transcription factor Complex-Inducing Compounds (TCIPs) for the treatment of MLL-rearranged leukemia, a particularly aggressive form of blood cancer. Prior to this, her research focused on bispecific antibodies, prodrugs, and IL-15 based immunotherapeutics, with a vision to decouple efficacy from toxicity. Through a blend of basic science and translational applications, she aims to rewire oncogenic signaling pathways and enhance anti-tumor immunity. Her research combines drug discovery, systems biology, and precision oncology, pushing the boundaries of targeted cancer treatment.

📚 Publications Top Notes:

  1. 🔬 Quantitative flow cytometry using quantitative streptavidin-protein G-biotin beads (qBeads) – J Immunol Methods, 2025

  2. 🧬 A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-directed Cell Death – Cell (revising)

  3. 💉 Enhance IL15 anti-tumor efficacy by inhibiting its negative feedback mechanism – (in preparation)

  4. ⚛️ Decouple the toxicity and efficacy of BJ-001, an integrin targeting IL-15 – AACR Abstract, 2019

  5. 🔄 Decoupling the toxicity and efficacy of immunotherapeutics – SITC Abstract, 2019

  6. 🧪 An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL – Leukemia & Lymphoma, 2020

  7. 🧫 A novel AKR1C3 specific prodrug TH3424 with potent anti-tumor activity in liver cancer – Clin Pharmacol Ther, 2021

  8. 🧲 A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity – J Vis Exp, 2018

  9. 🧠 Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies – Cancer Biol Ther, 2020

  10. 🧿 Bp-Bs, a novel T-cell engaging bispecific antibody with biparatopic Her2 binding – Mol Ther Oncolytics, 2019

  11. 🧰 A novel multi-functional anti-CEA-IL15 molecule displays potent anti-tumor activities – Drug Des Devel Ther, 2018

  12. 🧠 A single domain based anti-Her2 antibody has potent anti-tumor activities – Transl Oncol, 2018

🧾 Conclusion:

Dr. Yanlan Wang is highly deserving of the Best Researcher Award. Her contributions to cancer therapeutics through novel molecular approaches, her collaborations with globally renowned labs, and her publication record reflect a researcher of exceptional caliber and promise. With a deep understanding of tumor biology, a commitment to innovation, and a growing leadership presence in oncology research, she is not only suitable for the award but stands as a strong role model for future biomedical researchers.

Chenlong YANG | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Chenlong YANG | Cancer Cell Biology | Best Researcher Award

Prof. Chenlong YANG, Peking University Third Hospital, China

Dr. Chenlong Yang, M.D., Ph.D., is an accomplished neurosurgeon and research associate professor at the Department of Neurosurgery, Peking University Third Hospital. With over 15 years of clinical and research experience, he specializes in neuro-oncology, spinal neurosurgery, and translational neuroscience. Dr. Yang earned his M.D. from Shandong University and his Ph.D. in Neurological Surgery from Capital Medical University. He has trained and worked in prestigious institutions including Beijing Tiantan Hospital and the State Key Laboratory of Vascular Homeostasis and Remodeling. He has contributed significantly to advancements in brain tumor diagnostics, neuroimmunology, and surgical innovations, with numerous high-impact publications. Recognized internationally, he frequently presents at top neurosurgical conferences such as EANS and the Japan-China Neurosurgery Alliance. His research bridges basic science and clinical neurosurgery, aiming to improve surgical precision and therapeutic outcomes. Dr. Yang is also known for his leadership in collaborative, multidisciplinary research teams.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. 📚 Robust Academic and Clinical Training

    • Earned an M.D. from Shandong University and a Ph.D. in Neurological Surgery from Capital Medical University.

    • Completed clinical training at Beijing Tiantan Hospital, a top-tier neurosurgical institution in China.

  2. 🔬 Multidisciplinary and Translational Research Excellence

    • His research spans neuro-oncology, neuroimmunology, spinal neurosurgery, and advanced neuroimaging.

    • Conducted preclinical work on Alzheimer’s disease models and neuroprotection, along with current research in immune checkpoint therapy and intraoperative imaging.

  3. 📈 High-Impact Publications

    • Over 20 peer-reviewed publications in journals such as Scientific Reports, J Exp Clin Cancer Res, Neurosurgical Review, and Biophysical Journal.

    • His research on chordomas, gliomas, and spinal tumors has significantly contributed to the field.

  4. 🌍 International Recognition

    • Speaker at major international conferences like EANS 2025 and KSNS 2024.

    • Previously awarded a scholarship by the Turkish Neurosurgical Society.

  5. 🤝 Leadership in Collaboration

    • Plays a key role at the Center for Precision Neurosurgery and Oncology and the State Key Laboratory of Vascular Homeostasis and Remodeling, fostering interdisciplinary collaborations across neurosurgery, imaging, and immunotherapy.

  6. 🎯 Focus on Precision and Innovation

    • Pioneering high-resolution MRI techniques, fluorescent intraoperative navigation, and predictive modeling for neurosurgical outcomes.

🔄 Areas for Improvement:

  1. 📊 Independent Research Lead

    • While he has several corresponding author papers, increasing his share of first-author or sole-PI grants would further elevate his research identity.

  2. 🌐 Global Collaborations

    • Though he has spoken at international conferences, expanding collaborative projects with leading global neuroscience centers could amplify impact.

  3. 💡 Technology Commercialization

    • Given his innovation in imaging and diagnostics, pursuing intellectual property rights or translational funding (e.g., for clinical tools or surgical systems) could be a valuable next step.

  4. 📄 Diversification of Research Outputs

    • A few review articles and meta-analyses would strengthen his role as a thought leader and field synthesizer.

📘 Education:

Dr. Yang pursued his foundational medical education at Shandong University, earning an M.D. in Clinical Medicine (2006–2011). This training provided a solid clinical base and early exposure to neurology and internal medicine. He then advanced to a doctoral program at Capital Medical University, Beijing (2011–2017), earning his Ph.D. in Neurological Surgery. During his Ph.D., he received specialized training in neurosurgical techniques and engaged in cutting-edge research, particularly focusing on neuro-oncology and degenerative neural diseases. As part of his early research career, he also worked at the Institute of Neurobiology, Shandong University, investigating neuroprotective agents and Alzheimer’s disease models. Dr. Yang’s academic journey is characterized by rigorous clinical training and scientific inquiry, equipping him with the knowledge and skills essential for bridging the gap between the lab bench and the operating room. His education laid a strong foundation for his future contributions to precision neurosurgery and translational neuroscience.

💼 Experience:

Dr. Yang has over a decade of diversified experience across top medical and research institutions. He currently serves as a Research Associate Professor and Attending Physician at the Department of Neurosurgery, Peking University Third Hospital (2020–present), where he leads several clinical and translational research projects. Prior to this, he completed a postdoctoral fellowship (2017–2020) in the Department of Orthopedics at the same hospital, emphasizing spinal and neuro-oncologic conditions. From 2011 to 2017, he worked as a resident in Neurosurgery at Beijing Tiantan Hospital, one of China’s premier neurosurgical centers, gaining extensive experience in surgical treatments and neurovascular procedures. His roles span clinical surgery, research coordination, and academic instruction. Additionally, he actively contributes to the Center for Precision Neurosurgery and Oncology and the State Key Laboratory of Vascular Homeostasis and Remodeling, leading initiatives to improve patient outcomes through interdisciplinary innovations in neurosurgical care.

🧠 Research Focus:

Dr. Chenlong Yang’s research integrates neurosurgery, oncology, immunology, and biomedical engineering. His primary focus lies in neuro-oncology, with a strong emphasis on chordoma biology, glioma immunotherapy, and molecular diagnostics. He explores immune checkpoint therapies, tumor microenvironment modulation, and the development of predictive models for neurosurgical complications such as postoperative delirium. Dr. Yang is also deeply involved in technological innovation in neurosurgery, investigating intraoperative fluorescence imaging, high-resolution MRI, and minimally invasive spinal techniques. His work on spatial learning, Alzheimer’s models, and neuroprotection during his early career continues to inform his translational research. He collaborates across disciplines, from molecular biologists to radiologists, aiming to build precision-guided therapeutic frameworks. His research is extensively published in journals like Scientific Reports, J Exp Clin Cancer Res, and Frontiers in Neurology. Through this work, Dr. Yang seeks to advance the standard of care in neurosurgical oncology and promote patient-specific interventions.

📚 Publication Top Notes:

  1. 🧬 SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas

  2. 🛡️ Cracking Chordoma’s Conundrum: Immune Checkpoints Provide a Potential Modality

  3. 🌱 From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms – a review

  4. 💡 Intraoperative fluorescence redefining neurosurgical precision

  5. 🧠 The evolution and integration of technology in spinal neurosurgery: A scoping review

  6. 👁️ Single-cell transcriptomic atlas of aging macaque ocular outflow tissues

  7. 🧮 Risk stratification and predictive modeling of postoperative delirium in chronic subdural hematoma

  8. 📶 Characteristic fingerprint spectrum of α-synuclein mutants on terahertz time-domain spectroscopy

  9. 🐒 Normative profile of retinal nerve fiber layer thickness in cynomolgus monkeys

  10. 🌀 Accurate diagnosis and treatment of sacral meningeal cysts using high-resolution MRI

  11. 🧪 Intraspinal hemangioblastomas: analysis of 92 cases in a single institution

🏁 Conclusion:

Dr. Chenlong Yang exemplifies the ideal profile of a cutting-edge clinician-scientist, merging neurosurgical precision with immunological insight and technological innovation. His commitment to patient-centered research, consistent academic output, and recognition on international platforms underscores his eligibility for the Best Researcher Award. With continued growth in independent leadership and global research impact, Dr. Yang is not only a deserving candidate now but is poised to become a prominent global figure in neurosurgical research in the years to come.

Tao Zhang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Tao Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Tao Zhang, South China Normal University, China

Dr. Tao Zhang is a distinguished Professor at the College of Biophotonics, South China Normal University, where he has been advancing the frontiers of chemical biology and phototheranostics. With a keen focus on developing innovative optical probes and imaging techniques for tumor diagnosis and treatment, Dr. Zhang has made significant contributions to the field of lanthanide chemistry and biomedical imaging. His academic journey spans from Ningbo University (MPhil) to earning his Ph.D. in Chemistry from Hong Kong Baptist University. As a corresponding author on numerous high-impact publications and a recipient of multiple prestigious provincial awards, Dr. Zhang has earned recognition for both research excellence and academic leadership. He is actively involved in interdisciplinary collaborations, producing over 40 peer-reviewed publications in journals such as Nature Communications, PNAS, JACS, and Advanced Science. His ongoing work addresses critical challenges in imaging-guided therapies for cancer under hypoxic and complex microenvironment conditions.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. 📈 Outstanding Research Output
    Dr. Zhang has published over 40 peer-reviewed articles in top-tier journals such as Nature Communications, Advanced Science, JACS, ACS Nano, and PNAS. These works cover cutting-edge topics in photodynamic therapy, tumor imaging, and nanotechnology—key areas in modern biomedical research.

  2. 🧪 Innovation in Biomedical Chemistry
    He has demonstrated consistent originality by designing oxygen-independent Type I pro-photosensitizers, reversible ratiometric photoacoustic probes, and multimodal imaging nanoplatforms, all of which target real-world challenges in hypoxic tumor environments.

  3. 🌏 National Recognition
    His research excellence has been recognized by prestigious awards such as the Special Support Program for Young Top-notch Talents of Guangdong Province and the Pearl River Science and Technology Rising Star of Guangzhou, both in 2018.

  4. 🎯 Multidisciplinary Expertise
    With a strong background in lanthanide chemistry, chemical biology, and optical imaging, Dr. Zhang successfully bridges multiple fields, demonstrating a holistic approach to solving biomedical challenges.

  5. 📚 Leadership Role
    As a corresponding author on many publications, he plays a leading role in both research direction and execution. His progression from Assistant to Full Professor between 2014 and 2021 further reflects his capability as a research leader.

🛠️ Areas for Improvement:

  1. 🌐 International Collaborations & Visibility
    While Dr. Zhang has co-authored with international researchers, expanding his global collaborative network through joint grants, keynote talks, or leadership in international consortia could further enhance his profile.

  2. 👨‍🏫 Public Outreach & Technology Transfer
    Increasing efforts in public science communication, patenting innovations, or transitioning lab technologies into clinical trials could strengthen his case for broader societal impact.

  3. 📢 Social & Digital Engagement
    A higher digital or social media presence (e.g., ResearchGate, Google Scholar metrics, professional website updates) would make his research more visible to the global community and potential collaborators.

🎓 Education:

Dr. Tao Zhang embarked on his academic career with an MPhil in Inorganic Chemistry from Ningbo University (2006–2009), where he conducted research under Professor Hongze Liang. He furthered his education by pursuing a Ph.D. in Chemistry at Hong Kong Baptist University (2009–2013), mentored by Professors Wai-Kwok Wong and Ka-Leung Wong. His doctoral research focused on lanthanide coordination chemistry and bioimaging, setting a strong foundation for his future innovations in photodynamic therapy and tumor diagnostics. These formative years not only shaped his technical expertise in spectroscopy and nanomaterials but also cultivated a rigorous research ethic that has carried through his academic trajectory. His education was marked by cross-disciplinary training in synthetic chemistry, photophysics, and biological applications, providing him with a broad and robust skill set that continues to support his ongoing exploration in chemical biology and optical probes for clinical imaging and therapeutic interventions.

💼 Experience:

Dr. Zhang’s academic career at South China Normal University’s College of Biophotonics began in 2014 as an Assistant Professor. He was promoted to Associate Professor in 2017 and then to full Professor in 2021. Throughout his academic appointments, Dr. Zhang has led innovative research in tumor imaging, photothermal therapy, and optical diagnostics, establishing a productive research group known for creative nanoprobe design and translational research. His lab has secured multiple research grants and frequently collaborates with international researchers, combining chemical innovation with biomedical applications. Dr. Zhang has mentored graduate students and postdocs, many of whom have gone on to prestigious research positions. His steady academic progression reflects both his research productivity and leadership in the field of phototheranostics. Over the years, his expertise has positioned him at the forefront of integrating nanotechnology and chemistry into next-generation diagnostic and therapeutic platforms for treating cancer and understanding tumor microenvironments.

🏆 Awards and Honors:

Dr. Tao Zhang has received multiple prestigious awards that underscore his exceptional research contributions and scientific leadership. In 2018, he was honored with the Special Support Program for Young Top-notch Talents of Guangdong Province, recognizing his pioneering work in optical molecular probes for cancer imaging. That same year, he also received the Pearl River Science and Technology Rising Star of Guangzhou, further validating the impact and innovation of his interdisciplinary research in chemical biology. These accolades highlight his rising prominence as a researcher capable of translating basic chemical discoveries into practical medical technologies. He is consistently invited to contribute as a corresponding author in top-tier journals, reflecting the high regard his peers have for his scientific insight and rigor. These honors not only reflect personal achievement but also enhance the prestige of the College of Biophotonics at South China Normal University, where he continues to lead cutting-edge research.

🔍 Research Focus:

Dr. Tao Zhang’s research focuses on the convergence of Chemical Biology, Lanthanide Chemistry, and Optical Imaging Technologies for cancer diagnosis and treatment. His main interest lies in developing smart, light-activated nanomaterials and photosensitizers that enable precise imaging and phototherapy, particularly in hypoxic tumor microenvironments. His team is advancing Type I photodynamic therapy agents and oxygen-independent systems, addressing critical limitations in current cancer treatment modalities. Another core area of his research is the creation of upconversion nanoparticles and ratiometric probes for real-time, non-invasive imaging—capable of dual-modality functionality (fluorescence and photoacoustic). Leveraging lanthanide chemistry, Dr. Zhang also contributes to MRI contrast agent innovation and multimodal diagnostics. His cross-disciplinary work integrates synthetic chemistry, molecular design, and biological application, offering new avenues for theranostics. His cutting-edge research is published in leading journals, pushing the boundaries of tumor imaging, molecular sensing, and personalized cancer therapy with minimal invasiveness and enhanced specificity.

📚 Publications Top Notes:

  1. 🧬 Totally Caged Type I Pro-Photosensitizer for Oxygen-Independent Synergistic Phototherapy of Hypoxic Tumors – Advanced Science, 2024

  2. 🔁 Switching the NIR Upconversion of Nanoparticles for Orthogonal Activation of Photoacoustic Imaging and Phototherapy – Nature Communications, 2022

  3. 🧪 Dynamic-Reversible Photoacoustic Probe for Continuous Ratiometric Sensing and Imaging of Redox Status In Vivo – JACS, 2019

  4. 🎯 In Vivo Imaging-Guided Photothermal/Photoacoustic Synergistic Therapy with Tumor-Targeting Nanoparticles – ACS Nano, 2017

  5. 💥 In Vivo Selective Cancer-Tracking Gadolinium Eradicator as New-Generation Photodynamic Therapy Agent – PNAS, 2014

  6. 🧫 ROS-Catalytic Self-Amplifying Benzothiophenazine-Based Photosensitive Conjugates for Photodynamic-Immuno Therapy – Biomaterials, 2025

  7. 🧬 A Self-Catalytic UCNP-Based Nanomachine for Highly Sensitive Detection of CTCs – Biosensors and Bioelectronics, 2025

  8. 🔍 An AND-Gate Photoacoustic Probe for Cys and H2S Precise Photoacoustic Sensing in Tumors – Anal. Chem., 2024

  9. 🎨 Single Side-Chain-Modulatory of Hemicyanine for Fluorescence and Photoacoustic Dual-Modality Imaging – Small Methods, 2024

  10. 🌫️ High-Contrast Photoacoustic Imaging of Localized Cysteine in Breast Cancer – Chem. Eur. J., 2024

🧾 Conclusion:

Dr. Tao Zhang is highly suitable for the Best Researcher Award due to his exceptional scholarly output, innovative biomedical applications, and proven academic leadership. His work addresses some of the most critical challenges in cancer diagnostics and therapy using chemical tools and photonic technology.

HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Prof. Dr. WAN-JEONG JEONG , Department of Nuclear Medicine, Molecular Imaging Therapeutic Medicine Research Center, Jeonbuk Regional Cyclotron Research Center & Biotracer Imaging Lab. Jeonbuk National University Medical School & Hospital, South Korea

Dr. Hwan-Jeong Jeong is a distinguished leader in the field of nuclear medicine, currently serving as Director and Professor at Jeonbuk National University Medical School & Hospital, South Korea. With over two decades of academic and clinical experience, Dr. Jeong has pioneered research in molecular imaging, photobiomodulation, and radiopharmaceutical science. He has made impactful contributions to translational oncology, neuroimaging, and light-based therapeutics. With over 120 peer-reviewed publications, 33 patents, and an H-index of 44, his work bridges the gap between basic science and clinical innovation. Recognized for advancing image-guided therapy and precision diagnostics, he also actively collaborates across global institutions and serves as Associate Editor for Nuclear Medicine and Molecular Imaging. A recipient of multiple national and international recognitions, Dr. Jeong’s efforts continue to shape the future of medical imaging and cancer therapeutics. His commitment to integrating engineering and medicine marks him as a global innovator in nuclear and molecular medicine.

Publication Profile:

Orcid

✅ Strengths for the Award:

  • Outstanding Academic and Clinical Background: Dr. Jeong holds an MD, a Master’s in Medical Engineering, and a PhD in Medicine, with postdoctoral training at the prestigious MD Anderson Cancer Center.

  • Leadership in Research: As Director of multiple research centers, he has led over 20 high-impact projects, overseen 5 industry collaborations, and contributed to 120+ SCI-indexed publications.

  • Innovation & Translation: Holder of 33 patents, Dr. Jeong is a pioneer in integrating photobiogoverning, PET/CT imaging, and light-based cancer therapy, bridging lab discoveries and clinical application.

  • Global Recognition: Editorial board role in Nuclear Medicine and Molecular Imaging, and a consistent H-index of 44, reflect international impact and scientific credibility.

  • Cutting-Edge Contributions: Known for novel developments in blue light phototherapy, tumor-targeted radiopharmaceuticals, and noninvasive neuroimaging, significantly advancing cancer and neurological diagnostics.

⚠️ Areas for Improvement:

  • Broader International Collaboration: While highly respected in Korea and internationally, formalizing more international co-research programs or multicenter trials could further expand global reach.

  • Public Engagement & Science Communication: Increasing public visibility through science outreach, open-access publications, or global lectures/webinars can elevate the societal impact of his research.

  • Interdisciplinary Expansion: Potential to integrate AI-based imaging analysis or bioinformatics tools into existing molecular imaging and diagnostics research may boost next-gen innovation.

🎓 Education:

Dr. Hwan-Jeong Jeong began his academic journey at Chonnam National University, where he earned his MD in 1993, followed by a Master’s in Medical Engineering in 2000, and a Ph.D. in Medicine in 2003. He pursued his residency in Nuclear Medicine at Chonnam National University Hospital, gaining a strong clinical foundation. To further enhance his research capabilities, he completed a prestigious postdoctoral fellowship at MD Anderson Cancer Center, University of Texas, Houston, between 2008–2010. His educational path reflects an interdisciplinary approach—blending clinical medicine, biomedical engineering, and advanced imaging sciences. With an emphasis on nuclear medicine and optical diagnostics, Dr. Jeong’s educational background has strategically positioned him at the intersection of clinical practice and high-impact research. His academic evolution reflects a consistent dedication to innovation, translational research, and global collaboration.

🧪 Experience:

Dr. Jeong has served as Director and Professor of Nuclear Medicine at Jeonbuk National University Medical School & Hospital since 2005. His professional journey began with clinical training and residency, evolving into a global research career that includes a pivotal postdoctoral role at MD Anderson Cancer Center. Over the years, he has directed more than 20 research projects, consulted on 5 industry collaborations, and published over 120 scientific papers. Dr. Jeong holds 33 patents, highlighting his innovation in photomedicine and molecular imaging. He leads multiple advanced imaging centers and research labs, including the Molecular Imaging Therapeutic Medicine Research Center and Jeonbuk Regional Cyclotron Research Center. Internationally respected, he also serves as an Associate Editor for Nuclear Medicine and Molecular Imaging. His experience combines clinical expertise, leadership in research infrastructure, and international collaborations that foster innovation and patient-centered imaging solutions.

🔬 Research Focus:

Dr. Jeong’s research lies at the nexus of nuclear medicine, molecular imaging, and photobiomodulation therapy. His groundbreaking work integrates blue light phototherapy, PET/CT molecular imaging, radiopharmaceutical development, and fiber-optic–guided treatment systems for cancers and neurological disorders. He has made significant advances in FDG-PET imaging, amyloid brain scans, and light-triggered tumor therapies, facilitating precision diagnostics and targeted interventions. A key innovator in photobiogoverning—the biological control via light—Dr. Jeong has translated preclinical concepts into clinical applications through rigorous trials and device validation. His projects often explore the interface between biomedical optics and nano-diagnostics, enhancing real-time monitoring and minimally invasive treatments. Through cross-disciplinary collaborations and cutting-edge device design, he has shaped protocols that merge imaging with therapy for high-impact patient outcomes. His research aligns closely with future directions in personalized medicine and oncology imaging.

📚 Publications Top Notes:

  • 📘 From molecular mechanisms to clinical applications: A comprehensive review of photobiomodulation in cancer treatment

  • 📘 Blue-light activated nanoplatforms for image-guided cancer therapy

  • 📘 Clinical applications of brain amyloid PET imaging in neurodegenerative diseases

  • 📘 Multimodal theranostics using PET/CT and photodynamic therapy in head and neck cancer

  • 📘 Innovative radiotracers for monitoring tumor hypoxia and therapeutic response

  • 📘 Fiber-optic–based interstitial phototherapy in liver malignancies: A pilot clinical study

  • 📘 Nanomedicine-based nuclear imaging in virus-infected tissues

  • 📘 Bioluminescent imaging in evaluating immunotherapy response in solid tumors

  • 📘 Therapeutic implications of photobiogoverning in minimally invasive oncology

  • 📘 Noninvasive tracking of neuroinflammation using fluorinated PET probes

🧾 Conclusion:

Dr. Hwan-Jeong Jeong is an exceptionally qualified nominee for the Best Researcher Award. His contributions to nuclear medicine, molecular imaging, and light-based therapies exemplify academic excellence, clinical innovation, and translational impact. His body of work aligns closely with the award’s values—scientific rigor, real-world application, and forward-thinking medical solutions. With ongoing work in precision diagnostics and phototherapy, he not only meets but exceeds the standards expected of top global researchers in biomedical science. Dr. Jeong’s profile is a model of interdisciplinary leadership, making him a compelling and well-deserved recipient for this prestigious recognition.